We’ll get there soon

For people with extremely high triglycerides, despite standard of care

Imagine lowering the risk of acute pancreatitis by achieving the expert guideline-recommended goal for triglycerides <500 mg/dL

Explore More

Imagine achieving the guideline-recommended goal
for triglycerides

People with extremely high triglycerides, >880 mg/dL, who do not respond to traditional triglyceride-lowering therapies need treatment to lower their risk of acute pancreatitis. Strict diets can lower triglyceride levels but are hard to maintain, while traditional triglyceride-lowering therapies do not lower triglycerides enough to adequately reduce acute pancreatitis risk.

Reducing the risk of acute pancreatitis

Imagine if we could reduce acute pancreatitis risk by getting more people to the guideline-recommended goal. Endocrinology, cardiology, and lipidology experts agree that keeping triglyceride levels <500 mg/dL is the goal to reduce the risk of acute pancreatitis.

See the risk

[500-delay]

Expert guidelines across specialties consistently establish triglyceride levels of <500 mg/dL as the goal for triglyceride management to reduce acute pancreatitis risk.

A standing woman smiling while showing off her floral dress.

Guidelines from the National Lipid Association, the American Association of Clinical Endocrinology, the American College of Endocrinology, the American
College of Cardiology, and the American Heart Association all establish triglycerides <500 mg/dL as the goal to reduce acute pancreatitis risk.

We’ll get there [soon]

There are few options to keep triglycerides in check

For some people, the use of traditional triglyceride-lowering therapies and intensive dieting are not enough 
to lower levels and reduce acute pancreatitis risk.

See the impact

siRNA may hold the key to managing extremely high triglycerides

Silencing genes with siRNA (small interfering RNA) could be in our future.

See how siRNA works

Show References
  1. Chait A. Hypertriglyceridemia. Endocrinol Metab Clin North Am. 2022;51(3):539-555. 
  2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046-e1081. 
  3. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 executive summary. Endocr Pract. 2020;26(10):1196-1224. 
  4. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-993. 
  5.  Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9(2):129-169. 
  6. Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis. 2019;283:137-142. 
  7. Mszar R, Bart S, Sakers A, Soffer D, Karalis DG. Current and emerging therapies for atherosclerotic cardiovascular disease risk reduction in hypertriglyceridemia. J Clin Med. 2023;12(4):1382. doi: 10.3390/jcm12041382. 
  8. Shamsudeen I, Hegele RA. Safety and efficacy of therapies for chylomicronemia. Expert Rev Clin Pharmacol. 2022;15(4):395-405. 
  9. Williams L, Rhodes KS, Karmally W, et al. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. J Clin Lipidol. 2018;12(4):908-919.
  10. Watts GF. Shooting the Messenger to Treat Hypertriglyceridemia. N Engl J Med. 2024;390(19):1818-1823.